$CURR announced this week’s start of its initial Pharmacokinetics (PK)/bioequivalence studies in support of a previously approved Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). https://finance.yahoo.com/news/cure-pharmaceu...;tsrc=twtr